Related Experiment Videos
Pathophysiology and clinical importance of hyperhomocysteinemia: clinical intervention studies
G Sunder-Plassmann1, M Födinger
1Universtitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse, Universität Wien, Austria. sunder@nephro.imed3.akh-wien.ac.at
Insights
High homocysteine levels increase cardiovascular disease risk. Recent studies on folic acid and vitamin therapy show promising insights into lowering homocysteine, though cardiovascular outcomes require further investigation.
Area of Science:
- Cardiovascular Disease Research
- Nutritional Biochemistry
Background:
- Hyperhomocysteinemia is a recognized risk factor for cardiovascular disease (CVD) in both the general population and individuals with renal failure.
- Elevated homocysteine levels contribute to atherogenesis and thrombogenesis, impacting cardiovascular health.
Purpose of the Study:
- To summarize recent intervention studies aimed at lowering total homocysteine levels.
- To review findings in both non-renal failure and renal failure patient populations.
- To highlight emerging insights into the impact of folic acid and vitamin therapy on homocysteine levels and potential CVD outcomes.
Main Methods:
- Review of recent clinical intervention studies focusing on homocysteine-lowering therapies.
- Analysis of studies involving folic acid and vitamin supplementation.
- Examination of data from both general populations and patients with renal failure.
Main Results:
- Multiple studies have demonstrated the efficacy of folic acid and vitamin therapy in reducing total homocysteine levels.
- The primary focus of most studies has been the homocysteine-lowering effect, with less emphasis on direct cardiovascular disease outcomes.
- Recent research is beginning to provide important insights into the clinical implications of these interventions.
Conclusions:
- Folic acid and vitamin therapies are effective in lowering total homocysteine.
- Further research is needed to establish a definitive link between homocysteine reduction and improved cardiovascular disease outcomes.
- Understanding the role of homocysteine in renal failure patients warrants continued investigation.
Abstract:
Hyperhomocysteinemia is a cardiovascular disease risk factor in the general population and in patients with renal failure. This article summarizes the results of recent total homocysteine-lowering intervention studies in individuals without renal failure and in patients with renal failure. Although almost all of the published studies mainly focused on the total homocysteine-lowering effect and not on cardiovascular disease outcomes of folic acid and vitamin therapy, recent work has gained important insights into this area of developing concern.